Nostetta has invested in a privately owned biopharmaceutical company Aurealis Pharma. The company based in Kuopio, Finland and Basel, Switzerland, has developed an effective, safe and economical treatment method that greatly improves the quality of life for chronic inflammation and cancer sufferers.